The current status of adjuvant treatment for high-risk renal cell carcinoma

• Published in: Future oncology (London, England) Vol. 13; no. 23; pp. 2017 - 2020
• Main Authors: H zal, Mutlu, endur, Mehmet AN, Bilgin, Burak, Ak nc, Muhammed Bülent, ener Dede, Didem, Yalç n, Bulent
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.10.2017
• Subjects: adjuvant treatment; Clinical trials; Histology; Kidney cancer; Metastasis; Pathogenesis; Patients; renal cell carcinoma; tyrosine kinase inhibitors; Vascular endothelial growth factor; tyrosine kinase inhibitors; renal cell carcinoma; adjuvant treatment
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2017-0352

The treatment arms (1:1:1) received 54weeks of sunitinib 50mg per day orally throughout the first 4weeks of each 6week cycle, sorafenib 400mg twice per day orally throughout each cycle or placebo. Because of the poor tolerance and high discontinuation rates (44% in sunitinibarm and 45% in sorafenib arm), the starting dose was reduced sunitinib at 37.5mg daily and sorafenib at 400mg daily for one or two cycles and then up to original doses in the absence of significant side effects. [...]the investigators of S-TRAC emphasized the differences of study design and patient selection. [...]S-TRAC assessed DFS with blinded central review but the results of ASSURE processed by investigators (5 ,6). The patients received pazopanib or placebo for 1year after nephrectomy. Because of the high rates of discontinuation and tolerability problems starting dose of the drug was lowered from 800mg daily to 600mg daily after 403 patients had been treated.